Label: GENONE- gentamicin sulfate spray

  • NDC Code(s): 13985-566-12, 13985-566-24, 13985-566-60
  • Packager: MWI
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Animal Drug Application

Drug Label Information

Updated September 24, 2015

If you are a consumer or patient please visit this version.

  • INFORMATION FOR OWNERS/CAREGIVERS

    Veterinary

    For Topical Use in Dogs Only

    For Animal Use Only

  • CAUTION:

    Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION:

    Each mL contains: gentamicin sulfate, USP equivalent to 0.57 mg gentamicin base, betamethasone valerate, USP equivalent to 0.284 mg betamethasone, 163 mg isopropyl alcohol, propylene glycol, methylparaben and propylparaben as preservatives, purified water q.s. Hydrochloric acid may be added to adjust pH.

  • CHEMISTRY:

    Gentamicin is a mixture of aminoglycoside antibiotics derived from the fermentation of Micromonospora purpurea. Gentamicin sulfate veterinary is a mixture of sulfate salts of the antibiotics produced in this fermentation. The salts are weakly acidic and freely soluble in water.

    Gentamicin sulfate veterinary contains not less than 500 micrograms of gentamicin base per milligram.

    Betamethasone valerate is a synthetic glucocorticoid.

  • PHARMACOLOGY:

    Gentamicin, a broad-spectrum antibiotic, is a highly effective topical treatment for bacterial infections of the skin. In vitro, gentamicin is bactericidal against a wide variety of gram-positive and gram-negative bacteria isolated from domestic animals.1,2 Specifically, gentamicin is active against the following organisms isolated from canine skin: Alcaligenes sp., Citrobacter sp., Klebsiella sp., Pseudomonas aeruginosa, indole-positive and -negative Proteus sp., Escherichia coli, Enterobacter sp., Staphylococcus sp., and Streptococcus sp. Betamethasone valerate emerged from intensive research as the most promising of some 50 newly synthesized corticosteroids in the experimental model described by McKenzie,3 et al.

    This human bioassay technique has been found reliable for evaluating the vasoconstrictor properties of new topical corticosteroids and is useful in predicting clinical efficacy.

    Betamethasone valerate in veterinary medicine has been shown to provide anti-inflammatory and antipruritic activity in the topical management of corticosteroid-responsive infected superficial lesions in dogs.

  • WARNING:

    Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

    Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congential anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs that received corticosteroids during pregnancy.

  • INDICATIONS:

    For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.

    Keep Out of Reach of Children.

  • CONTRAINDICATIONS:

    If hypersensitivity to any of the components occurs, discontinue treatment and institute appropriate therapy.

  • DOSAGE AND ADMINISTRATION:

    Prior to treatment, remove excessive hair and clean the lesion and adjacent area. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer 2 to 4 times daily for 7 days.

    Each depression of the sprayer head delivers 0.7 mL of GenOne Spray.

  • TOXICITY:

    GenOne Spray was well-tolerated in an abraded skin study in dogs. No treatment-related toxicological changes in the skin were observed.

    Systemic effects directly related to treatment were confined to histological changes in the adrenals, liver, and kidney and to organ-to-body weight ratios of adrenals. All were dose related, were typical for or not unexpected with corticosteroid therapy, and were considered reversible with cessation of treatment.

  • SIDE EFFECTS:

    Side effects such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs.

    Cushing’s syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

  • PRECAUTIONS:

    Antibiotic susceptibility of the pathogenic organism(s) should be determined prior to use of this preparation. Use of topical antibiotics may permit overgrowth of nonsusceptible bacteria, fungi, or yeasts. If this occurs, treatment should be instituted with other appropriate agents as indicated.

    Administration of recommended dose beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely.

    Avoid ingestion. Oral or parenteral use of corticosteroids, depending on dose, duration, and specific steroid may result in inhibition of endogenous steroid production following drug withdrawal.

    In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations.

    If ingestion should occur, patients should be closely observed for the usual signs of adrenocorticoid overdosage that include sodium retention, potassium loss, fluid retension, weight gains, polydipsia, and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.

  • HOW SUPPLIED:

    Plastic spray bottles containing 60 mL, 120 mL and 240 mL of GenOne Spray

    Store upright between 2° and 30°C (36° and 86°F).

  • REFERENCES:

    1. Hennessy PW, et al. In vitro activity of gentamicin against bacteria isolated from domestic animals. Veterinary Medicine/SmallAnimalClinician. November 1971; 1118-1122.
    2. Bachmann HJ, et al. Comparative in vitro activity of gentamicin and other antibiotics against bacteria isolated from clinical samples from dogs, cats, horses, and cattle. Veterinary Medicine/Small Animal Clinician.  October 1975; 1218-1222.
    3. McKenzie HW, Atkinson RM. Topical activities of betamethasone esters in man. Arch Derm. May 1964; 741-746.

    Distributed by: MWI

    Boise, ID 83705

    (888)694-8381

    www.VetOne.net

    Revision 06/14 (60 mL)

    Revision 01/14 (120 mL & 240 mL)

    ANADA# 200-415, Approved by FDA

  • PRINCIPAL DISPLAY PANEL

    Front Display Panel - 60 mL

    image of 60 mL bottle label - Front panel

    Inside Panel - 60 mL

    image of 60 mL bottle label - Inside panel

    (rev. 03/15)

  • PRINCIPAL DISPLAY PANEL

    Front Display Panel - 120 mL

    image of 120 mL bottle label - Front Panel

    Inside Panel - 120 mL bottle

    image of 120 mL bottle label - Inside Panel

    (rev. 06/15)

  • PRINCIPAL DISPLAY PANEL

    Bottle Display Panel - 240 mL

    image of 240 mL bottle label - Front Panel

    Inside Panel - 240 mL bottle

    image of 240 mL bottle label - Inside Panel

    (rev. 06/15)

  • INGREDIENTS AND APPEARANCE
    GENONE 
    gentamicin sulfate spray
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:13985-566
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GENTAMICIN SULFATE (UNII: 8X7386QRLV) (GENTAMICIN - UNII:T6Z9V48IKG) GENTAMICIN0.0599 g  in 100 mL
    BETAMETHASONE VALERATE (UNII: 9IFA5XM7R2) (BETAMETHASONE - UNII:9842X06Q6M) BETAMETHASONE0.0352 g  in 100 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:13985-566-6012 in 1 CASE
    160 mL in 1 BOTTLE, SPRAY
    2NDC:13985-566-1212 in 1 CASE
    2120 mL in 1 BOTTLE, SPRAY
    3NDC:13985-566-2412 in 1 CASE
    3240 mL in 1 BOTTLE, SPRAY
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20041509/02/2014
    Labeler - MWI (019926120)
    Establishment
    NameAddressID/FEIBusiness Operations
    FIRST PRIORITY INCORPORATED179925722manufacture
    Establishment
    NameAddressID/FEIBusiness Operations
    FUJIAN FUKANG PHARMACEUTICAL CO., LTD.528180884api manufacture